全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

靶向突变型p53的肿瘤治疗策略研究进展
Research Progress on Targeted Therapeutic Strategies for Mutant p53 in Cancer

DOI: 10.12677/wjcr.2026.162010, PP. 77-89

Keywords: p53,突变型p53,靶向治疗,蛋白降解靶向嵌合体
p53
, Mutant p53, Targeted Therapy, Proteolysis-Targeting Chimera (PROTAC)

Full-Text   Cite this paper   Add to My Lib

Abstract:

p53是人类恶性肿瘤中突变频率最高的抑癌基因,其功能状态直接影响肿瘤的发生发展、治疗应答及患者预后。在正常生理状态下,p53作为基因组稳定性的关键调控者,通过诱导细胞周期阻滞、细胞凋亡及DNA修复等机制发挥核心抑癌功能。然而,TP53基因突变不仅导致其经典功能丧失,更赋予突变蛋白新的致癌活性,从而驱动肿瘤的侵袭转移、代谢重编程、治疗耐药及免疫微环境重塑等恶性进程。本综述系统阐述了p53蛋白的结构基础与核心生物学功能,重点剖析了突变型p53获得性致癌功能的分子机制。在此基础上,聚焦于直接靶向突变型p53的前沿治疗策略:基于蛋白降解靶向嵌合体等新技术的突变体清除策略、通过构象校正恢复野生型功能的再激活剂研发,以及特异性干预其异常致癌蛋白互作网络的创新方法。这些策略体现了从传统功能抑制到靶向干预的转变,为克服p53突变相关临床治疗困境提供了新的方向,对该领域的深入探索与未来发展具有重要的参考价值。
p53 is the most frequently mutated tumor suppressor gene in human malignancies, whose functional status directly influences tumor initiation, progression, therapeutic response, and patient prognosis. Under normal physiological conditions, p53 acts as a critical regulator of genome stability, exerting its core tumor-suppressive functions through mechanisms including cell cycle arrest, apoptosis induction, and DNA repair. However, mutations in the TP53 gene not only lead to the loss of these classical functions but often confer oncogenic activities to the mutant protein, thereby driving malignant processes such as tumor invasion and metastasis, metabolic reprogramming, therapy resistance, and immune microenvironment remodeling. This review systematically elaborates on the structural basis and core biological functions of the p53 protein, with a focused analysis of the molecular mechanisms underlying the gain-of-function oncogenic properties of mutant p53. Furthermore, it concentrates on advanced therapeutic strategies directly targeting mutant p53: mutation clearance strategies based on novel technologies such as proteolysis-targeting chimeras, the development of reactivators that restore wild-type function through conformational correction, and innovative methods to specifically disrupt its aberrant oncogenic protein interaction networks. These strategies represent a shift from traditional functional inhibition to precise targeted intervention, offering new directions for addressing the clinical challenges associated with p53 mutations. This work holds significant reference value for the continued exploration and future development of this research field.

References

[1]  Wang, H., Guo, M., Wei, H. and Chen, Y. (2023) Targeting p53 Pathways: Mechanisms, Structures and Advances in Therapy. Signal Transduction and Targeted Therapy, 8, Article No. 92.
https://doi.org/10.1038/s41392-023-01347-1
[2]  Xu, B., Maimaitijiang, A., Nuerbiyamu, D., Su, Z. and Li, W. (2025) The Multifaceted Role of p53 in Cancer Molecular Biology: Insights for Precision Diagnosis and Therapeutic Breakthroughs. Biomolecules, 15, Article 1088.
https://doi.org/10.3390/biom15081088
[3]  Song, B., Yang, P. and Zhang, S. (2024) Cell Fate Regulation Governed by p53: Friends or Reversible Foes in Cancer Therapy. Cancer Communications, 44, 297-360.
https://doi.org/10.1002/cac2.12520
[4]  Cordani, M., Pacchiana, R., Butera, G., D’Orazi, G., Scarpa, A. and Donadelli, M. (2016) Mutant p53 Proteins Alter Cancer Cell Secretome and Tumour Microenvironment: Involvement in Cancer Invasion and Metastasis. Cancer Letters, 376, 303-309.
https://doi.org/10.1016/j.canlet.2016.03.046
[5]  Blandino, G., Valenti, F., Sacconi, A. and Di Agostino, S. (2020) Wild Type-and Mutant p53 Proteins in Mitochondrial Dysfunction: Emerging Insights in Cancer Disease. Seminars in Cell & Developmental Biology, 98, 105-117.
https://doi.org/10.1016/j.semcdb.2019.05.011
[6]  Stiewe, T. and Haran, T.E. (2018) How Mutations Shape p53 Interactions with the Genome to Promote Tumorigenesis and Drug Resistance. Drug Resistance Updates, 38, 27-43.
https://doi.org/10.1016/j.drup.2018.05.001
[7]  Chen, Y., Wu, Y., Yang, H., Li, X., Jie, M., Hu, C., et al. (2018) Prolyl Isomerase Pin1: A Promoter of Cancer and a Target for Therapy. Cell Death & Disease, 9, Article No. 883.
https://doi.org/10.1038/s41419-018-0844-y
[8]  Shu, K., Li, B. and Wu, L. (2007) The p53 Network: p53 and Its Downstream Genes. Colloids and Surfaces B: Biointerfaces, 55, 10-18.
https://doi.org/10.1016/j.colsurfb.2006.11.003
[9]  Joerger, A.C. and Fersht, A.R. (2008) Structural Biology of the Tumor Suppressor p53. Annual Review of Biochemistry, 77, 557-582.
https://doi.org/10.1146/annurev.biochem.77.060806.091238
[10]  Raj, N. and Attardi, L.D. (2017) The Transactivation Domains of the p53 Protein. Cold Spring Harbor Perspectives in Medicine, 7, a026047.
https://doi.org/10.1101/cshperspect.a026047
[11]  Zhang, Y. and Dutta, M. (2025) The Multifunctional Proline-Rich Domain of p53 Tumor Suppressor. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 1880, Article ID: 189326.
https://doi.org/10.1016/j.bbcan.2025.189326
[12]  Strano, S., Munarriz, E., Rossi, M., Castagnoli, L., Shaul, Y., Sacchi, A., et al. (2001) Physical Interaction with Yes-Associated Protein Enhances p73 Transcriptional Activity. Journal of Biological Chemistry, 276, 15164-15173.
https://doi.org/10.1074/jbc.m010484200
[13]  Hoyos, D., Greenbaum, B. and Levine, A.J. (2022) The Genotypes and Phenotypes of Missense Mutations in the Proline Domain of the p53 Protein. Cell Death & Differentiation, 29, 938-945.
https://doi.org/10.1038/s41418-022-00980-7
[14]  Berger, M., Vogt Sionov, R., Levine, A.J. and Haupt, Y. (2001) A Role for the Polyproline Domain of p53 in Its Regulation by Mdm2. Journal of Biological Chemistry, 276, 3785-3790.
https://doi.org/10.1074/jbc.m008879200
[15]  Olivier, M., Hollstein, M. and Hainaut, P. (2009) TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harbor Perspectives in Biology, 2, a001008-a001008.
https://doi.org/10.1101/cshperspect.a001008
[16]  Gencel-Augusto, J. and Lozano, G. (2020) p53 Tetramerization: At the Center of the Dominant-Negative Effect of Mutant p53. Genes & Development, 34, 1128-1146.
https://doi.org/10.1101/gad.340976.120
[17]  Nie, L., Sasaki, M. and Maki, C.G. (2007) Regulation of p53 Nuclear Export through Sequential Changes in Conformation and Ubiquitination. Journal of Biological Chemistry, 282, 14616-14625.
https://doi.org/10.1074/jbc.m610515200
[18]  Bode, A.M. and Dong, Z. (2004) Post-Translational Modification of p53 in Tumorigenesis. Nature Reviews Cancer, 4, 793-805.
https://doi.org/10.1038/nrc1455
[19]  Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. and Elledge, S.J. (1993) The p21 CDK-Interacting Protein Cip1 Is a Potent Inhibitor of G1 Cyclin-Dependent Kinases. Cell, 75, 805-816.
https://doi.org/10.1016/0092-8674(93)90499-g
[20]  Gorjala, P., Cairncross, J.G. and Gary, R.K. (2016) p53-Dependent Up-Regulation of CDKN1A and Down-Regulation of CCNE2 in Response to Beryllium. Cell Proliferation, 49, 698-709.
https://doi.org/10.1111/cpr.12291
[21]  Rother, K., Kirschner, R., Sänger, K., Böhlig, L., Mössner, J. and Engeland, K. (2006) p53 Downregulates Expression of the G1/S Cell Cycle Phosphatase Cdc25a. Oncogene, 26, 1949-1953.
https://doi.org/10.1038/sj.onc.1209989
[22]  Hermeking, H., Lengauer, C., Polyak, K., He, T., Zhang, L., Thiagalingam, S., et al. (1997) Is a p53-Regulated Inhibitor of G2/M Progression. Molecular Cell, 1, 3-11.
https://doi.org/10.1016/s1097-2765(00)80002-7
[23]  Zhan, Q., Chen, I., Antinore, M.J. and Fornace, A.J. (1998) Tumor Suppressor p53 Can Participate in Transcriptional Induction of the GADD45 Promoter in the Absence of Direct DNA Binding. Molecular and Cellular Biology, 18, 2768-2778.
https://doi.org/10.1128/mcb.18.5.2768
[24]  Krause, K., Wasner, M., Reinhard, W., Haugwitz, U., Dohna, C.L., Mössner, J., et al. (2000) The Tumour Suppressor Protein p53 Can Repress Transcription of Cyclin B. Nucleic Acids Research, 28, 4410-4418.
https://doi.org/10.1093/nar/28.22.4410
[25]  Fischer, M., Quaas, M., Steiner, L. and Engeland, K. (2015) The p53-p21-DREAM-CDE/CHR Pathway Regulates G2/M Cell Cycle Genes. Nucleic Acids Research, 44, 164-174.
https://doi.org/10.1093/nar/gkv927
[26]  Innocente, S.A., Abrahamson, J.L.A., Cogswell, J.P. and Lee, J.M. (1999) p53 Regulates a G2 Checkpoint through Cyclin B1. Proceedings of the National Academy of Sciences, 96, 2147-2152.
https://doi.org/10.1073/pnas.96.5.2147
[27]  Taylor, W.R., DePrimo, S.E., Agarwal, A., Agarwal, M.L., Schönthal, A.H., Katula, K.S., et al. (1999) Mechanisms of G2 Arrest in Response to Overexpression of p53. Molecular Biology of the Cell, 10, 3607-3622.
https://doi.org/10.1091/mbc.10.11.3607
[28]  Quaas, M., Müller, G.A. and Engeland, K. (2012) p53 Can Repress Transcription of Cell Cycle Genes through a p21WAF1/CIP1-Dependent Switch from MMB to DREAM Protein Complex Binding at CHR Promoter Elements. Cell Cycle, 11, 4661-4672.
https://doi.org/10.4161/cc.22917
[29]  Mannefeld, M., Klassen, E. and Gaubatz, S. (2009) B-MYB Is Required for Recovery from the DNA Damage-Induced G2 Checkpoint in p53 Mutant Cells. Cancer Research, 69, 4073-4080.
https://doi.org/10.1158/0008-5472.can-08-4156
[30]  Fischer, M., Quaas, M., Nickel, A. and Engeland, K. (2015) Indirect p53-Dependent Transcriptional Repression of Survivin, CDC25C, and PLK1 Genes Requires the Cyclin-Dependent Kinase Inhibitor p21/cdkn1a and CDE/CHR Promoter Sites Binding the DREAM Complex. Oncotarget, 6, 41402-41417.
https://doi.org/10.18632/oncotarget.6356
[31]  Wei, M.C., Zong, W., Cheng, E.H.-., Lindsten, T., Panoutsakopoulou, V., Ross, A.J., et al. (2001) Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death. Science, 292, 727-730.
https://doi.org/10.1126/science.1059108
[32]  Tait, S.W.G. and Green, D.R. (2013) Mitochondrial Regulation of Cell Death. Cold Spring Harbor Perspectives in Biology, 5, a008706.
https://doi.org/10.1101/cshperspect.a008706
[33]  Yu, J. and Zhang, L. (2008) PUMA, a Potent Killer with or without p53. Oncogene, 27, S71-S83.
https://doi.org/10.1038/onc.2009.45
[34]  Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., Newmeyer, D.D., Schuler, M., et al. (2004) Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis. Science, 303, 1010-1014.
https://doi.org/10.1126/science.1092734
[35]  Leu, J.I., Dumont, P., Hafey, M., Murphy, M.E. and George, D.L. (2004) Mitochondrial p53 Activates Bak and Causes Disruption of a Bak-Mcl1 Complex. Nature Cell Biology, 6, 443-450.
https://doi.org/10.1038/ncb1123
[36]  Stennicke, H.R., Jürgensmeier, J.M., Shin, H., Deveraux, Q., Wolf, B.B., Yang, X., et al. (1998) Pro-Caspase-3 Is a Major Physiologic Target of Caspase-8. Journal of Biological Chemistry, 273, 27084-27090.
https://doi.org/10.1074/jbc.273.42.27084
[37]  Mirza, A., McGuirk, M., Hockenberry, T.N., Wu, Q., Ashar, H., Black, S., et al. (2002) Human Survivin Is Negatively Regulated by Wild-Type p53 and Participates in p53-Dependent Apoptotic Pathway. Oncogene, 21, 2613-2622.
https://doi.org/10.1038/sj.onc.1205353
[38]  Budanov, A.V. and Karin, M. (2008) p53 Target Genes Sestrin1 and Sestrin2 Connect Genotoxic Stress and mTOR Signaling. Cell, 134, 451-460.
https://doi.org/10.1016/j.cell.2008.06.028
[39]  Lee, J. and Paull, T.T. (2004) Direct Activation of the ATM Protein Kinase by the Mre11/Rad50/Nbs1 Complex. Science, 304, 93-96.
https://doi.org/10.1126/science.1091496
[40]  Kastan, M.B., Zhan, Q., El-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V., et al. (1992) A Mammalian Cell Cycle Checkpoint Pathway Utilizing p53 and GADD45 Is Defective in Ataxia-Telangiectasia. Cell, 71, 587-597.
https://doi.org/10.1016/0092-8674(92)90593-2
[41]  Liu, P., Barkley, L.R., Day, T., Bi, X., Slater, D.M., Alexandrow, M.G., et al. (2006) The Chk1-Mediated S-Phase Checkpoint Targets Initiation Factor Cdc45 via a Cdc25a/Cdk2-Independent Mechanism. Journal of Biological Chemistry, 281, 30631-30644.
https://doi.org/10.1074/jbc.m602982200
[42]  Shats, I., Milyavsky, M., Tang, X., Stambolsky, P., Erez, N., Brosh, R., et al. (2004) p53-Dependent Down-Regulation of Telomerase Is Mediated by p21. Journal of Biological Chemistry, 279, 50976-50985.
https://doi.org/10.1074/jbc.m402502200
[43]  Tarapore, P. and Fukasawa, K. (2002) Loss of p53 and Centrosome Hyperamplification. Oncogene, 21, 6234-6240.
https://doi.org/10.1038/sj.onc.1205707
[44]  Momand, J., Zambetti, G.P., Olson, D.C., George, D. and Levine, A.J. (1992) The Mdm-2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation. Cell, 69, 1237-1245.
https://doi.org/10.1016/0092-8674(92)90644-r
[45]  Haupt, Y., Maya, R., Kazaz, A. and Oren, M. (1997) MDM2 Promotes the Rapid Degradation of p53. Nature, 387, 296-299.
https://doi.org/10.1038/387296a0
[46]  Shvarts, A., Steegenga, W.T., Riteco, N., van Laar, T., Dekker, P., Bazuine, M., et al. (1996) MDMX: A Novel p53-Binding Protein with Some Functional Properties of MDM2. The EMBO Journal, 15, 5349-5357.
https://doi.org/10.1002/j.1460-2075.1996.tb00919.x
[47]  Wade, M., Li, Y. and Wahl, G.M. (2013) MDM2, MDMX and p53 in Oncogenesis and Cancer Therapy. Nature Reviews Cancer, 13, 83-96.
https://doi.org/10.1038/nrc3430
[48]  Appella, E. and Anderson, C.W. (2001) Post-Translational Modifications and Activation of p53 by Genotoxic Stresses. European Journal of Biochemistry, 268, 2764-2772.
https://doi.org/10.1046/j.1432-1327.2001.02225.x
[49]  Cheng, Q., Chen, L., Li, Z., Lane, W.S. and Chen, J. (2009) ATM Activates p53 by Regulating MDM2 Oligomerization and E3 Processivity. The EMBO Journal, 28, 3857-3867.
https://doi.org/10.1038/emboj.2009.294
[50]  Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M.D., Beck, H.P., et al. (2014) Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development. Journal of Medicinal Chemistry, 57, 1454-1472.
https://doi.org/10.1021/jm401753e
[51]  Wang, S., Zhao, Y., Aguilar, A., Bernard, D. and Yang, C. (2017) Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. Cold Spring Harbor Perspectives in Medicine, 7, a026245.
https://doi.org/10.1101/cshperspect.a026245
[52]  Ballarotto, M., Bianconi, E., Valentini, S., Temperini, A., Moretti, F. and Macchiarulo, A. (2024) Rational Design, Synthesis, and Biophysical Characterization of a Peptidic MDM2-MDM4 Interaction Inhibitor. Bioorganic & Medicinal Chemistry, 113, Article ID: 117937.
https://doi.org/10.1016/j.bmc.2024.117937
[53]  Tornesello, M. (2025) TP53 Mutations in Cancer: Molecular Features and Therapeutic Opportunities (Review). International Journal of Molecular Medicine, 55, Article No. 7.
https://doi.org/10.3892/ijmm.2024.5448
[54]  Liu, J., Shen, Y., Liu, J., Xu, D., Chang, C., Wang, J., et al. (2025) Lipogenic Enzyme FASN Promotes Mutant p53 Accumulation and Gain-of-Function through Palmitoylation. Nature Communications, 16, Article No. 1762.
https://doi.org/10.1038/s41467-025-57099-9
[55]  Xu, J., Jiao, J., Xu, W., Ji, L., Jiang, D., Xie, S., et al. (2017) Mutant p53 Promotes Cell Spreading and Migration via Arhgap44. Science China Life Sciences, 60, 1019-1029.
https://doi.org/10.1007/s11427-016-9040-8
[56]  Boudreau, H.E., Ma, W.F., Korzeniowska, A., Park, J.J., Bhagwat, M.A. and Leto, T.L. (2017) Histone Modifications Affect Differential Regulation of TGFβ-Induced NADPH Oxidase 4 (NOX4) by Wild-Type and Mutant p53. Oncotarget, 8, 44379-44397.
https://doi.org/10.18632/oncotarget.17892
[57]  Bykov, V.J.N., Eriksson, S.E., Bianchi, J. and Wiman, K.G. (2017) Targeting Mutant p53 for Efficient Cancer Therapy. Nature Reviews Cancer, 18, 89-102.
https://doi.org/10.1038/nrc.2017.109
[58]  Huang, X., Zhang, Y., Tang, Y., Butler, N., Kim, J., Guessous, F., et al. (2013) A Novel PTEN/Mutant p53/C-MYC/BCL-XL Axis Mediates Context-Dependent Oncogenic Effects of PTEN with Implications for Cancer Prognosis and Therapy. Neoplasia, 15, 952-965.
https://doi.org/10.1593/neo.13376
[59]  Tsou, S., Hou, M., Hsu, L., Chen, T. and Chen, Y. (2015) Gain-of-Function p53 Mutant with 21-bp Deletion Confers Susceptibility to Multidrug Resistance in MCF-7 Cells. International Journal of Molecular Medicine, 37, 233-242.
https://doi.org/10.3892/ijmm.2015.2406
[60]  Tan, B.S., Tiong, K.H., Choo, H.L., Fei-Lei Chung, F., Hii, L., Tan, S.H., et al. (2015) Mutant p53-R273h Mediates Cancer Cell Survival and Anoikis Resistance through Akt-Dependent Suppression of Bcl2-Modifying Factor (BMF). Cell Death & Disease, 6, e1826-e1826.
https://doi.org/10.1038/cddis.2015.191
[61]  Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., et al. (2013) Tumour-Associated Mutant p53 Drives the Warburg Effect. Nature Communications, 4, Article No. 2935.
https://doi.org/10.1038/ncomms3935
[62]  Freed-Pastor, W.A., Mizuno, H., Zhao, X., Langerød, A., Moon, S., Rodriguez-Barrueco, R., et al. (2012) Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell, 148, 244-258.
https://doi.org/10.1016/j.cell.2011.12.017
[63]  Cooks, T., Pateras, I.S., Tarcic, O., Solomon, H., Schetter, A.J., Wilder, S., et al. (2013) Mutant p53 Prolongs NF-κB Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer. Cancer Cell, 23, 634-646.
https://doi.org/10.1016/j.ccr.2013.03.022
[64]  Cooks, T., Pateras, I.S., Jenkins, L.M., Patel, K.M., Robles, A.I., Morris, J., et al. (2018) Mutant p53 Cancers Reprogram Macrophages to Tumor Supporting Macrophages via Exosomal miR-1246. Nature Communications, 9, Article No. 771.
https://doi.org/10.1038/s41467-018-03224-w
[65]  Joerger, A.C. and Fersht, A.R. (2016) The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Annual Review of Biochemistry, 85, 375-404.
https://doi.org/10.1146/annurev-biochem-060815-014710
[66]  Dahiya, V., Agam, G., Lawatscheck, J., Rutz, D.A., Lamb, D.C. and Buchner, J. (2019) Coordinated Conformational Processing of the Tumor Suppressor Protein p53 by the Hsp70 and Hsp90 Chaperone Machineries. Molecular Cell, 74, 816-830.e7.
https://doi.org/10.1016/j.molcel.2019.03.026
[67]  Sharp, S. and Workman, P. (2006) Inhibitors of the HSP90 Molecular Chaperone: Current Status. Advances in Cancer Research, 95, 323-348.
[68]  Chai, K., Ning, X., Nguyễn, T.T.T., Zhong, B., Morinaga, T., Li, Z., et al. (2018) Heat Shock Protein 90 Inhibitors Augment Endogenous Wild-Type p53 Expression but Down-Regulate the Adenovirally-Induced Expression by Inhibiting a Proteasome Activity. Oncotarget, 9, 26130-26143.
https://doi.org/10.18632/oncotarget.25452
[69]  Ryu, H., Shin, D., Lee, D.H., Choi, J., Han, G., Lee, K.Y., et al. (2017) HDAC6 Deacetylates p53 at Lysines 381/382 and Differentially Coordinates p53-Induced Apoptosis. Cancer Letters, 391, 162-171.
https://doi.org/10.1016/j.canlet.2017.01.033
[70]  Parrales, A., Ranjan, A., Iyer, S.V., Padhye, S., Weir, S.J., Roy, A., et al. (2016) DNAJA1 Controls the Fate of Misfolded Mutant p53 through the Mevalonate Pathway. Nature Cell Biology, 18, 1233-1243.
https://doi.org/10.1038/ncb3427
[71]  Kong, L., Meng, F., Zhou, P., Ge, R., Geng, X., Yang, Z., et al. (2024) An Engineered DNA Aptamer-Based PROTAC for Precise Therapy of p53-R175h Hotspot Mutant-Driven Cancer. Science Bulletin, 69, 2122-2135.
https://doi.org/10.1016/j.scib.2024.05.017
[72]  Lambert, J.M.R., Gorzov, P., Veprintsev, D.B., Söderqvist, M., Segerbäck, D., Bergman, J., et al. (2009) PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain. Cancer Cell, 15, 376-388.
https://doi.org/10.1016/j.ccr.2009.03.003
[73]  Haffo, L., Lu, J., Bykov, V.J.N., Martin, S.S., Ren, X., Coppo, L., et al. (2018) Inhibition of the Glutaredoxin and Thioredoxin Systems and Ribonucleotide Reductase by Mutant p53-Targeting Compound Apr-246. Scientific Reports, 8, Article No. 12671.
https://doi.org/10.1038/s41598-018-31048-7
[74]  Denko, N.C. (2008) Hypoxia, HIF1 and Glucose Metabolism in the Solid Tumour. Nature Reviews Cancer, 8, 705-713.
https://doi.org/10.1038/nrc2468
[75]  Narayanan, D., Ma, S. and Özcelik, D. (2020) Targeting the Redox Landscape in Cancer Therapy. Cancers, 12, Article 1706.
https://doi.org/10.3390/cancers12071706
[76]  Kummar, S., Fellous, M. and Levine, A.J. (2025) The Roles of Mutant p53 in Reprogramming and Inflammation in Breast Cancers. Cell Death & Differentiation, 32, 1949-1953.
https://doi.org/10.1038/s41418-025-01549-w
[77]  Santini, V., Stahl, M. and Sallman, D.A. (2024) TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. American Society of Clinical Oncology Educational Book, 44, e432650.
https://doi.org/10.1200/edbk_432650
[78]  Liu, X., Wilcken, R., Joerger, A.C., Chuckowree, I.S., Amin, J., Spencer, J., et al. (2013) Small Molecule Induced Reactivation of Mutant p53 in Cancer Cells. Nucleic Acids Research, 41, 6034-6044.
https://doi.org/10.1093/nar/gkt305
[79]  Puzio-Kuter, A.M., Xu, L., McBrayer, M.K., Dominique, R., Li, H.H., Fahr, B.J., et al. (2025) Restoration of the Tumor Suppressor Function of Y220c-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator. Cancer Discovery, 15, 1159-1179.
https://doi.org/10.1158/2159-8290.cd-24-1421
[80]  Zhou, S., Chai, D., Wang, X., Neeli, P., Yu, X., Davtyan, A., et al. (2023) AI-Powered Discovery of a Novel p53-Y220c Reactivator. Frontiers in Oncology, 13, Article 1229696.
https://doi.org/10.3389/fonc.2023.1229696
[81]  Fujihara, K.M., Zhang, B.Z., Jackson, T.D., Ogunkola, M.O., Nijagal, B., Milne, J.V., et al. (2022) Eprenetapopt Triggers Ferroptosis, Inhibits NFS1 Cysteine Desulfurase, and Synergizes with Serine and Glycine Dietary Restriction. Science Advances, 8, eabm9427.
https://doi.org/10.1126/sciadv.abm9427
[82]  Zhou, F., Sun, Y., Chen, X., Wu, D., Tao, Z., Wu, L., et al. (2025) UBE2T-Mediated Hp1α Ubiquitination Enhances Nucleolar Function and Promotes the Progression of IDH1/TP53-Mutant Glioma. Clinical Cancer Research, 31, 3970-3983.
https://doi.org/10.1158/1078-0432.ccr-25-0261
[83]  Loureiro, J.B., Ribeiro, R., Nazareth, N., Ferreira, T., Lopes, E.A., Gama, A., et al. (2022) Mutant p53 Reactivator SLMP53-2 Hinders Ultraviolet B Radiation-Induced Skin Carcinogenesis. Pharmacological Research, 175, Article ID: 106026.
https://doi.org/10.1016/j.phrs.2021.106026
[84]  Miller, J.J., Kwan, K., Blanchet, A., Orvain, C., Mellitzer, G., Smith, J., et al. (2023) Multifunctional Metallochaperone Modifications for Targeting Subsite Cavities in Mutant p53-Y220c. Journal of Inorganic Biochemistry, 242, Article ID: 112164.
https://doi.org/10.1016/j.jinorgbio.2023.112164
[85]  Khadiullina, R., Chasov, V., Gilyazova, E., Davletshin, D., Mirgayazova, R., Mingaleeva, R., et al. (2025) Cellular Activity Upregulation of the Thermolabile p53 Cancer Mutant Y220C by Small Molecule Indazole Derivatives. Cell Death Discovery, 11, Article No. 508.
https://doi.org/10.1038/s41420-025-02781-6
[86]  Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., et al. (2006) Gain of Function of Mutant p53: The Mutant p53/NF-Y Protein Complex Reveals an Aberrant Transcriptional Mechanism of Cell Cycle Regulation. Cancer Cell, 10, 191-202.
https://doi.org/10.1016/j.ccr.2006.08.013
[87]  Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T. and Prives, C. (2001) A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain. Molecular and Cellular Biology, 21, 1874-1887.
https://doi.org/10.1128/mcb.21.5.1874-1887.2001
[88]  Kravchenko, J.E., Ilyinskaya, G.V., Komarov, P.G., Agapova, L.S., Kochetkov, D.V., Strom, E., et al. (2008) Small-molecule RETRA Suppresses Mutant p53-Bearing Cancer Cells through a p73-Dependent Salvage Pathway. Proceedings of the National Academy of Sciences, 105, 6302-6307.
https://doi.org/10.1073/pnas.0802091105

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133